Previous 10 | Next 10 |
Penske Automotive Group Inc. (PAG) is expected to report $3.66 for Q4 2023 Copa Holdings S.A. Class A (CPA) is expected to report $3.9 for Q4 2023 Wynn Resorts Limited (WYNN) is expected to report $1.12 for Q4 2023 U-Haul Holding Co Com (UHAL) is expected to report $0.82 for Q3 2024 ...
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2023 financial results and provide a business update on Wednesday, February 7, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a c...
COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH ® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidi...
2024-01-29 12:14:29 ET More on Ascendis Pharma Ascendis Pharma's Ambitious Vision 2030 Ascendis Pharma: Skytrofa Net Sales Not The Update Investors Are Waiting For Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript Jefferies starts Ascendis at buy, c...
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together wi...
2024-01-27 19:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-16 21:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-11 08:33:08 ET Summary Ascendis Pharma outlined its Vision 2030 ahead of and during the J.P. Morgan Healthcare Conference. The company expects three endocrinology products to achieve blockbuster status, pipeline to expand in rare disease endocrinology and to mass market in...
DUBAI, United Arab Emirates, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vector Pharma FZCO (Vector) today announced that it has entered into an exclusive distribution agreement with Danish company Ascendis Pharma A/S (Nasdaq: ASND) to commercialize both Skytrofa ™ and Yorvipath ™ in ...
Strategic roadmap to achieve blockbuster status for multiple products and expand the Company’s engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vi...
News, Short Squeeze, Breakout and More Instantly...
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada Canada NewsWire MONTREAL , July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distributio...
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose • Improvements could not be explained by changes in linear growth only, supporti...
2024-06-19 21:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...